Chemokine (C-X-C motif) ligand 1 (CXCL1) and chemokine (C-X-C motif) ligand 2 (CXCL2) modulate the activity of TRPV1+/IB4+ cultured rat dorsal root ganglia neurons upon short-term and acute application.

CXCL1 and CXCL2 are two chemokines with 78% homology of their sequence. CXCL1 was associated with atopic dermatitis, a highly pruritic skin disease, but it is not clear what is its mechanism of action, while for CXCL2 there are no data about an association with itch sensitivity. CXCL1 and CXCL2 can modulate TRPV1 receptors, which are one of the most important downstream effectors for itch sensitivity, upon short-term (4 h) or long-term (24 h) incubation, but the data are incomplete. Therefore, the aims of this study were to better characterize the short-term effects of CXCL1 and CXCL2 on TRPV1+/IB4+ dorsal root ganglia neurons known to include nociceptor and itch-sensitive neurons, and to obtain new data about the acute application (12 min) of the two chemokines on the same population of neurons. The results showed that 4 nM CXCL1 and 3.6 nM CXCL2 significantly reduce TRPV1 desensitization in TRPV1+/IB4+ DRG +neurons after short-term incubation, but when acutely applied CXCL1 activated a sub-population of itch-sensitive TRPV1+/IB4+ cells in a slow, low amplitude manner, while CXCL2 had a similar effect but on non-itch TRPV1+/IB4+ DRG neurons. These data contribute to a better understanding of CXCL1 and CXCL2 mechanism of action for both pain and itch inducing effects.

Catecholamines reduce transient receptor potential vanilloid type 1 desensitization in cultured dorsal root ganglia neurons.

Sympathetic nervous system and adrenergic receptors are involved in the modulation of dorsal root ganglia neuronal activity, with TRPV1 receptor as an important downstream effector. It is already known that adrenergic sensitization of TRPV1 receptors or catecholamine-induced TRPV1 upregulation are involved in increased excitability and pain via mainly α1 adrenergic receptors, but it is not known if reduced TRPV1 desensitization is involved in this process, as well. Therefore, the aims of this study were to evaluate the effects of epinephrine and norepinephrine on TRPV1 desensitization induced by repeated applications of capsaicin and to assess what would be the involvement of the major α1, α2 and ß adrenergic receptor subtypes. Using calcium microfluorimetry, the effects were evaluated by exposure to 1 µM epinephrine or 10 µM norepinephrine, alone or in the presence of adrenergic receptor inhibitors (phentolamine, prazosin and propranolol) before a 4th capsaicin application in a series of 5 consecutive capsaicin applications. The results showed that both catecholamines produced significant reduction of TRPV1 desensitization, which was mediated by α1, α2 and ß2 receptors. This study completes the general information about TRPV1 sensitization via adrenergic stimulation and may open perspectives for novel pharmacological approaches in skin inflammatory disorders and pain therapy.